On June 16, 2025, Pulmovant, a Roivant company, announced the publication of Phase 1 pharmacokinetics (PK) and lung deposition data for inhaled mosliciguat. The peer-reviewed manuscript, published in Clinical Pharmacokinetics, details results from studies in healthy male volunteers. These studies characterize the pharmacokinetic profile of mosliciguat after inhalation.
The data indicate that inhaled mosliciguat has a longer half-life compared to oral and intravenous administration, supporting once-daily dosing. Crucially, the studies showed no evidence of serious systemic side effects, with no discernible impact on systemic systolic blood pressure. This favorable safety profile is a key differentiator for the potential first-in-class inhaled sGC activator.
These positive Phase 1 results informed the ongoing Phase 2 PHocus study of mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). The publication validates mosliciguat's targeted delivery to the lungs and its potential to provide an effective treatment option for patients with this progressive and life-threatening condition.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.